Science & Enterprise subscription

Follow us on Twitter

  • An academic-industry collaboration is creating a non-invasive technique to detect rupture-prone plaque build-ups in… https://t.co/U6v6tBF4PA
    about 9 hours ago
  • New post on Science and Enterprise: Math Model to Gauge Heart Attack Risk from Plaques https://t.co/7BIPROFhpv #Science #Business
    about 9 hours ago
  • National Institutes of Health is supporting development of an extended-release probiotic treatment for necrotizing… https://t.co/d99utcSRV1
    about 2 days ago
  • New post on Science and Enterprise: Small Biz Grant Funds Pre-Term Gut Microbe Therapy https://t.co/f7WmGFYOuD #Science #Business
    about 2 days ago
  • A company developing vaccines with synthetic biology is receiving a grant for a vaccine to prevent infections from… https://t.co/t5QBG7wnwO
    about 2 days ago

Please share Science & Enterprise

Recap – Editas Medicine Advances Crispr Therapy

Crispr genome edits illustration

(NIH.gov)

2 Dec. 2018. While much the world watched, and disapproved of, a Chinese researcher editing the genomes of embryos leading to the birth of twins, Editas Medicine in Cambridge, Massachusetts received the go-ahead to conduct a clinical trial using the genome editing technique Crispr. On Friday, the Food and Drug Administration, in an approved investigational new drug application, authorized Editas to test Crispr as a treatment for a rare inherited eye disease known as Leber congenital amaurosis type 10.

Here’s what else we reported on last week:

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.